Vendor comparison · 2026
Mecasermin (IGF-1) vendors: 0 compared on COAs and price
Tissue & recoveryAlso known as rhIGF-1, Recombinant IGF-1, Increlex
Evidence tier
Substantial published literature
295 publications over 40 years · trials not yet curated
- Vendors carrying it
- 0
- 0 with a listed price
- Vendors with checkable COAs
- 0
- 0 publish any certificate
- Lots tested
- 0
- 0 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- —
- Laboratories named
- 0
- Median label gap
- —
- Median purity
- —
- Lowest price per mg
- —
- Publications located
- 295
- researched since 1986
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
No indexed vendor publishes a Mecasermin (IGF-1) certificate naming a laboratory this index could check, so no vendor can be called well-tested for it yet. No vendor price for Mecasermin (IGF-1) is on record. 0 vendors carrying Mecasermin (IGF-1) are compared below. 0 publish at least one certificate naming a checkable laboratory, no lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Mecasermin (IGF-1)
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| No indexed vendor currently lists this compound. | |||||||||
Independent assays
No independently commissioned assay of Mecasermin (IGF-1) is on file. No certificate for it has been indexed at all. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
Laboratories used
No certificate for Mecasermin (IGF-1) names a laboratory this index could identify.
Every certificate record
No certificate record for Mecasermin (IGF-1) is indexed. Either no vendor publishes one, or those published could not be read without an account.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1986 — 40 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
295 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
No vendor testing policy recorded yet — nothing recorded yet
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Mecasermin (IGF-1)?
Recombinant human insulin-like growth factor-1 (mecasermin). It is an approved prescription medicine for severe primary IGF-1 deficiency and is listed by vendors here as a research material.
Studied in published research for growth and insulin-like growth factor-1 deficiency.
Regulatory status
Mecasermin is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- Mecasermin for primary insulin-like growth factor-1 deficiency — Australian prescriber (2022)
Peer-reviewed article indexed in PubMed, published in Australian prescriber (2022).
- Mecasermin — BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2008)
Peer-reviewed article indexed in PubMed, published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2008).
- Mecasermin rinfabate — Drugs of today (Barcelona, Spain : 1998) (2007)
Peer-reviewed article indexed in PubMed, published in Drugs of today (Barcelona, Spain : 1998) (2007).
- Mecasermin (recombinant human insulin-like growth factor I) — Advances in therapy (2009)
Peer-reviewed article indexed in PubMed, published in Advances in therapy (2009).
- Treatment with Recombinant Human Insulin-Like Growth Factor-1 in Severe Primary IGF Deficiency and Beyond — Hormone research in paediatrics (2015)
Peer-reviewed article indexed in PubMed, published in Hormone research in paediatrics (2015).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.